Format

Send to

Choose Destination
J Antimicrob Chemother. 1999 Feb;43(2):309-11.

Continuous infusion ceftazidime in intensive care: a randomized controlled trial.

Author information

1
Royal Brisbane Hospital, Division of Anaesthesiology and Intensive Care, University of Queensland, Brisbane, Australia. jlipman@gasbone.herston.uq.edu.au

Abstract

We randomized 18 critically ill patients to receive ceftazidime 6 g/day by continuous infusion or bolus dosing (2 g 8 hourly), each with a loading dose of 12 mg/kg ceftazidime. During the first 8 h, plasma ceftazidime concentration fell below 40 mg/L in only one patient (trough 38 mg/L) from the infusion group, compared with eight from the bolus group (2-33 mg/L) for periods ranging from 73 to 369 min. Thereafter all infusion patients remained above 40 mg/L for 40 h of study versus 20-30% of bolus patients. The pharmacokinetic and pharmacodynamic characteristics of ceftazidime suggest that continuous infusions should be clinically investigated in outcome studies.

PMID:
11252342
DOI:
10.1093/jac/43.2.309
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center